The Trump administration is planning an experiment to cover weight loss drugs under Medicare and Medicaid, potentially ...

Drugs known as GLP-1 receptor agonists were initially developed to treat Type 2 diabetes but have become a cultural ...

The Trump administration is considering a five-year pilot program to cover weight-loss drugs under Medicare and Medicaid, the ...

A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.

Trump is changing Medicare, mostly focusing on providers. But the biggest impact may come from tariffs and deporting ...

Proposed experiment would allow states and Medicare drug plans to cover GLP-1 drugs like Ozempic and Wegovy for obesity, The ...

U.S. President Donald Trump listens to remarks during a swearing-in ceremony for Administrator of the Centers for Medicare ...

Medicare and Medicaid could expand coverage of GLP-1 drugs, such as Ozempic and Wegovy, and pay for patients’ use of the ...

Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach for many obese Americans.

Thousands of Rhode Island seniors and disabled residents no longer covered for non-emergency visits at four local hospitals ...

Minnesota Gov. Tim Walz declared Wednesday "Medicaid and Medicare Day," and marked the day by discussing the anticipated ...